PT Meratus Jasa Prima Tbk (IDX:KARW)

Ligand Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	0.18	0.08	1.2	0.96	-0.59	0.07
Depreciation & Amortization	1.85	1.85	1.88	1.84	1.84	1.82
Other Operating Activities	-1.34	-0.71	-0	0.64	-0.27	-0.33
Operating Cash Flow	0.69	1.22	3.08	3.44	0.97	1.56
Operating Cash Flow Growth	-66.14%	-60.32%	-10.65%	253.28%	-37.52%	-61.34%
Capital Expenditures	-0.06	-0.1	-0.27	-0.11	-0.08	-0.02
Sale of Property, Plant & Equipment	0.01	-	-	0.02	-	-
Investing Cash Flow	-0.05	-0.1	-0.27	-0.09	-0.08	-0.02
Short-Term Debt Issued	-	-	-	0.22	-	-
Total Debt Issued	-	-	-	0.22	-	-
Short-Term Debt Repaid	-	-0.16	-3.32	-5.08	-1	-1
Long-Term Debt Repaid	-	-0.01	-0.06	-0.06	-0.06	-0.04
Total Debt Repaid	0.01	-0.17	-3.38	-5.14	-1.06	-1.04
Net Debt Issued (Repaid)	0.01	-0.17	-3.38	-4.92	-1.06	-1.04
Financing Cash Flow	0.01	-0.17	-3.38	-4.92	-1.06	-1.04
Foreign Exchange Rate Adjustments	0.09	0.06	-0.01	-0.08	-0.03	-0.04
Net Cash Flow	0.75	1.01	-0.58	-1.64	-0.19	0.46
Free Cash Flow	0.64	1.12	2.81	3.34	0.89	1.54
Free Cash Flow Growth	-67.33%	-60.19%	-15.81%	273.97%	-41.90%	-61.44%
Free Cash Flow Margin	12.04%	24.36%	41.41%	46.75%	30.41%	33.91%
Free Cash Flow Per Share	0.00	0.00	0.01	0.01	0.00	0.00
Cash Income Tax Paid	0.73	0.73	0.6	-0.05	-0.06	0.09
Levered Free Cash Flow	44.79	45.07	2.68	3.03	0.83	1.59
Unlevered Free Cash Flow	44.79	45.07	2.68	3.03	0.83	1.59

Updated Oct 29, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.